May. 1 at 7:46 PM
$CORT Path forward for Relacorilant/Cushing Syndrome:
- During the call, CEO Belanoff shifted the narrative away from the initial shock of the Q4 CRL and focused on active regulatory repair, and confirmed that engagement with FDA on the exact requirements to resolve the agency's concerns and the new NDA submission.
- Belanoff explicitly stated, "We will provide an update on relacorilant's regulatory path in the near future," (Discussion with FDA ongoing).
- Sean Maduck, President of Corcept Endocrinology, projected that the company's Cushing's syndrome business—currently driven by Korlym but heavily factoring in the future approval of relacorilant—is expected to grow to at least
$2 billion in annual revenue by the end of the decade. He noted that growth will accelerate significantly once relacorilant becomes commercially available.
